In this report, we present an update of the 2020 primary systematic review, to take into account more recent evidence on the efficacy, effectiveness and safety of newer and/or enhanced seasonal influenza vaccines for the prevention of laboratory-confirmed influenza in individuals aged 18 years and over.
This issue of the ECDC Communicable Disease Threats Report (CDTR) covers the period 31 March - 6 April 2024 and includes updates on SARS-CoV-2, cholera, avian influenza A(H5N1), swine influenza A(H1N2) and Middle East respiratory syndrome coronavirus (MERS-CoV).
The inaugural meeting of the EUHTF in January 2024 marked a significant milestone in strengthening the EU's preparedness and response capacity to face public health emergencies.
Since the beginning of 2024, and as of 3 April, no MERS-CoV cases have been reported by WHO or national health authorities. The last reported case was in Saudi Arabia, with date of onset on 26 October 2023.
The purpose of the Audit Committee is to assist the Management Board in fulfilling its oversight responsibilities for the financial reporting process, the system of internal control and the audit process.
In a joint report released today, ECDC and EFSA outline the contributing drivers for influenza A(H5N1) viruses to acquire the ability to spread efficiently among humans, thereby increasing their pandemic potential.
Avian influenza viruses (AIV) remain prevalent among wild bird populations in the European Union and European Economic Area (EU/EEA), leading to significant illness in and death of birds.